Effect of demographic variables, disease characteristics, and previous treatment on response (CR + PR) to bortezomib in univariate analysis
Characteristic . | No. in category/no. evaluable (%) . | CR or PR, % . | P . |
|---|---|---|---|
| Age, y | .064* | ||
| < 65 | 124/193 (64) | 32 | |
| ≥ 65 | 69/193 (36) | 19 | |
| Sex | .741* | ||
| Male | 118/193 (61) | 26 | |
| Female | 75/193 (39) | 29 | |
| Race | .064* | ||
| White | 157/193 (81) | 24 | |
| Black | 21/193 (11) | 48 | |
| Other | 15/193 (8) | 33 | |
| Body surface area (m2) | .403* | ||
| ≤ 2 | 123/193 (64) | 25 | |
| >2 | 70/193 (36) | 31 | |
| KPS | .524* | ||
| ≤ 70 | 34/188 (18) | 35 | |
| 80 | 74/188 (39) | 27 | |
| ≥ 90 | 80/188 (43) | 25 | |
| Previous therapy | |||
| Thalidomide | .675* | ||
| Yes | 159/193 (82) | 28 | |
| No | 34/193 (18) | 24 | |
| SCT/high-dose therapy | .504* | ||
| Yes | 122/193 (63) | 30 | |
| No | 71/193 (37) | 24 | |
| No. previous therapies | .419* | ||
| ≤ 5 | 91/193 (47) | 24 | |
| ≥ 6 | 102/193 (53) | 30 | |
| Hemoglobin concentration, g/L | .15 | ||
| <105 (10.5 g/dL) | 105/193 (54) | 23 | |
| ≥ 105 (10.5 g/dL) | 88/193 (46) | 33 | |
| Myeloma type | .414* | ||
| IgG | 116/190 (61) | 24 | |
| IgA | 47/190 (25) | 32 | |
| Light chain | 27/190 (14) | 33 | |
| Plasma-cell infiltration in bone marrow, % | .03* | ||
| > 50 | 85/178 (48) | 20 | |
| ≤ 50 | 93/178 (52) | 35 | |
| Cytogenetics | .047* | ||
| Abnormal | 57/162 (35) | 19 | |
| Normal | 105/162 (65) | 35 | |
| Chromosome 13 deletion | .636* | ||
| Yes | 25/162 (15) | 24 | |
| No | 137/162 (85) | 31 | |
| β2-microglobulin, mg/L | NA | 0.91† | .07‡ |
| Stage of disease | .32* | ||
| 1 | 46/174 | 35 | |
| 2 | 76/174 | 28 | |
| 3 | 52/174 | 21 |
Characteristic . | No. in category/no. evaluable (%) . | CR or PR, % . | P . |
|---|---|---|---|
| Age, y | .064* | ||
| < 65 | 124/193 (64) | 32 | |
| ≥ 65 | 69/193 (36) | 19 | |
| Sex | .741* | ||
| Male | 118/193 (61) | 26 | |
| Female | 75/193 (39) | 29 | |
| Race | .064* | ||
| White | 157/193 (81) | 24 | |
| Black | 21/193 (11) | 48 | |
| Other | 15/193 (8) | 33 | |
| Body surface area (m2) | .403* | ||
| ≤ 2 | 123/193 (64) | 25 | |
| >2 | 70/193 (36) | 31 | |
| KPS | .524* | ||
| ≤ 70 | 34/188 (18) | 35 | |
| 80 | 74/188 (39) | 27 | |
| ≥ 90 | 80/188 (43) | 25 | |
| Previous therapy | |||
| Thalidomide | .675* | ||
| Yes | 159/193 (82) | 28 | |
| No | 34/193 (18) | 24 | |
| SCT/high-dose therapy | .504* | ||
| Yes | 122/193 (63) | 30 | |
| No | 71/193 (37) | 24 | |
| No. previous therapies | .419* | ||
| ≤ 5 | 91/193 (47) | 24 | |
| ≥ 6 | 102/193 (53) | 30 | |
| Hemoglobin concentration, g/L | .15 | ||
| <105 (10.5 g/dL) | 105/193 (54) | 23 | |
| ≥ 105 (10.5 g/dL) | 88/193 (46) | 33 | |
| Myeloma type | .414* | ||
| IgG | 116/190 (61) | 24 | |
| IgA | 47/190 (25) | 32 | |
| Light chain | 27/190 (14) | 33 | |
| Plasma-cell infiltration in bone marrow, % | .03* | ||
| > 50 | 85/178 (48) | 20 | |
| ≤ 50 | 93/178 (52) | 35 | |
| Cytogenetics | .047* | ||
| Abnormal | 57/162 (35) | 19 | |
| Normal | 105/162 (65) | 35 | |
| Chromosome 13 deletion | .636* | ||
| Yes | 25/162 (15) | 24 | |
| No | 137/162 (85) | 31 | |
| β2-microglobulin, mg/L | NA | 0.91† | .07‡ |
| Stage of disease | .32* | ||
| 1 | 46/174 | 35 | |
| 2 | 76/174 | 28 | |
| 3 | 52/174 | 21 |